Recent Melanoma News

COMBI-v BRAF/MEK Inhibitor Combination Trial Continues to Impress in Melanoma (March 15, 2017)

For advanced melanoma patients with BRAF mutations, two pathway inhibitors are much better than one, according to a study presented at the European Society for Medical Oncology.  The latest data confirm... Continue Reading

Yervoy® Improves Overall Survival in Fully Resected Stage III Melanoma Patients (October 24, 2016)

Results were presented during the 2016 European Society for Medical Oncology Congress demonstrating that Yervoy® (ipilimumab) compared to placebo improves survival in stage III melanoma patients who are... Continue Reading

Epacadostat Plus Keytruda® Appears Effective in Melanoma (October 11, 2016)

The treatment combination consisting of epacadostat plus Keytruda® (pembrolizumab) appears effective in the treatment of advanced melanoma. Melanoma is a type of skin cancer that often starts in the form... Continue Reading

Cotellic®/Zelboraf® Combo: New Standard of Care for Melanoma (September 20, 2016)

The treatment combination consisting of Cotellic® (cobimetinib) plus Zelboraf® (vemurafenib) improves overall survival for patients with advanced, BRAF (V600) mutation-positive melanoma. These confirmatory... Continue Reading

3-Year Survival Improved with Taflinar®/Mekinist® Combination in Advanced Melanoma (July 21, 2016)

Patients with advanced melanoma who were treated with the combination consisting of Taflinar (dabrafenib) plus Mekinist (trametinib) had a significantly improved survival rate at 3 years compared to those... Continue Reading

Counsyl Announces Major Oncology Expansion to Advance Genetic Screening for Cancer Risk (May 25, 2016)

Counsyl launches oncology business unit, an expanded test to assess risk for inherited forms of cancer, and tools to improve genetic screening rates across the healthcare system Counsyl, a DNA testing... Continue Reading

Opdivo Receives Expanded Approval as Single Agent for Initial Therapy in Melanoma (December 2, 2015)

The United States Food and Drug Administration (FDA) has approved the PD1 inhibitor, Opdivo (nivolumab), as a single agent for initial therapy of advanced melanoma. This is the sixth indication for which... Continue Reading

Yervoy Gets Expanded Approval for Earlier-Stage Melanoma (November 9, 2015)

The United States Food and Drug Administration (FDA) has expanded the approval indication for Yervoy (ipilimumab) to include treatment of stage III melanoma. Melanoma is the most deadly form of skin cancer,... Continue Reading

Imlygic® Approved for Melanoma (October 28, 2015)

Imlygic® (talimogene laherparepvec), the first ever FDA-approved oncolytic virus therapy, has been approved for the treatment of melanoma. The approval is for the treatment of melanoma sites in the skin... Continue Reading

Opdivo® Alone or Combined with Yervoy® Effective in Advanced Melanoma (June 29, 2015)

Opdivo® (nivolumab) used alone or in combination with Yervoy® (ipilimumab) appears to extend progression-free survival in patients with advanced melanoma. These findings were presented at 2015 Annual... Continue Reading

« Previous PageNext Page »